Monday, February 11, 2013

P&G's move to EDC


Dear fellow executives,

Our company’s health care division is being held back by the inefficiencies associated with the traditional paper-based method of recording and archiving clinical trial data.   Our ‘time to lock’ process from when we collect the final piece of trial data to the locking of our database is approximately 8 weeks for our highest priority trials producing the fewest data errors.  Lesser priority or high issue trials often take double or triple that time.  These ‘time to lock’ delays when considered over three to four clinical trials ends up delaying our market entry times by 6 months to a year.  Estimates predict that each day of delay in market entry for a major prescription drug has the potential to cost us up to $1 million in lost sales.  Time isn’t just money; it’s the air that breathes life into the lungs of our health care business!  The manual nature of the paper approach is not only time consuming but also incredibly expensive.  Each phase 3 trial we conduct costs us just under $1 million in expenses related to printing, shipping and data entry for CRF forms alone – at  $9.25 per CRF page and approximately 10,000 total pages.  We are paying our CRAs a handsome $2500 per site visit and the current process requires more CRA visits than should be necessary.  Much of the time they spend at sites is spent identifying and ensuring the remediation of potential data errors.   Phase 1 to 3 trials in total can cost us $125 million out of pocket and are consuming 7 full years of a valuable 20-year patent life.  We must make clinical trials more efficient in terms of both time and cost.  We can do this is by adopting and carefully implementing web enabled Electronic Data Capture (EDC).

Web enabled EDC is a new system that utilizes the internet to allow data to be entered into the data management system directly by the investigative sites.  This data will then immediately become available to us for monitoring the trial and conducting blinded data analysis.  This approach will finally eliminate the need – and steep costs of associated with — the ancient art of double data entry.  With several hundred error checks coded directly into the eCRFs, EDC will provide automatic error checking.  This will allow investigators to identify and remediate potential data entry and patient qualification errors on the spot and in real-time.   This has the additional benefit of early notification on trial difficulties and can reduce the number of expensive onsite monitoring visits needed to be performed by CRAs.  We should opt to adopt the web interfaced EDC largely because it will be less difficult for the investigators to assimilate with, opposed to proprietary software.  While there will definitely be a learning curve associated with this switch, the fact that people are now becoming more comfortable with the internet with everyday use should make the transition to web based EDC less painful.  Phase Forward, our leading web based EDC provider candidate has agreed to include peripheral services that include developing and maintaining the eCRFs as well as providing help desk support for all our trial sites.  We have already conducted a handful of pilot trials with Phase Forward and I am very impressed with the results.  Our data entry costs have been slashed by better than 50% from $6 to $9 per CRF page down to only $3 to $4.  That translates to nearly $500,000 reduction in savings per trial.    We have realized an immediate positive impact on our ‘time to lock’.  Each trial has become progressively more efficient and by the fifth trial we had slashed the time to lock in half from 8 down to only 4 weeks.  Recalling that each day we gain potentially accounts for nearly $1 million in our top line sales, this is a serious return – already $28 million per trial phase.  And we believe we have the ability to drive the time to lock progressively lower, perhaps eventually to but only a handful of days.

Now without putting a serious damper those appealing benefits I need to raise caution to the potential challenges we may encounter with a transition to web enabled EDC.  I also want to address the costs involved with this investment.  One of the greatest hurdles will relate to resistance from users to adopting the new platform.  People are still becoming familiar with the internet and will be hesitant to adapt to a new process. Many will likely require extensive customized training in order to become proficient with web enabled EDC.  Patients and site administrators may have concerns about the privacy of their personal information being recorded by an internet based application.  While concerns may often be exaggerated, this is an issue we must treat seriously as data security is critical.   Occasionally slow or undependable internet connections could delay data flows from time to time.  Preparation times for trial set-up stages could initially be much longer with EDC.  But we believe that as an experience curve develops these prep times could be reduced to the same length of time as is customary with the paper approach.  While we are very impressed with Phase Forward, the fact is they are a relatively young company lacking a meaningful track record of success.  There will a leap of faith required in doing business with this company.  There will be considerable upfront costs associated with making sure all sites are fully equipped with the right technical resources.  We will need to purchase laptop computers for approximately 750 of our sites which will cost approximately $900,000.  We can also expect to pay around $500,000 in evaluations of all our sites to assess their computing capabilities.   After we have covered these initial costs we can expect to pay Phase Forward a fee from $250,000 to $450,000 per trial depending on the scope of the trial.

I have evaluated other options that include bolstering the current paper system or alternatively adopting a digital imaging system.  By paying to expedite the mailing of CRF binders and hiring additional staff members to increase the speed of site monitoring and source data verification we could potentially see a minor increase in the speed at which the current process moves.  However, these actions would not address the mechanical inefficiencies of the paper process which is inherently a tedious process.  Innately there will always be limitations to how fast this work can be performed by hand before significantly increasing the incidence of errors.  Digital imaging requires substantial investments in large scale database storage systems.  And after reviewing the digital imaging process the results revealed that it did not considerably improve review times compared to the paper process.

If we move quickly but carefully we seek to gain a competitive advantage in the pharmaceutical industry.  The upfront $1.4M investment and $250,000 to $450,000 in fees per trial can be more than offset by the immediate savings and potential to significantly increase sales by reducing the time it takes us to get to market.  As previously stated, we have already realized $500,000 savings per trial related to CRF related costs.  We have already seen CRA visits slashed in half translating to nearly $20,000 in savings per trial.  We could expect to see a large reduction in the $1,500 per site for fax related costs.  Compounded over time these collective savings are not to be ignored.  And the savings can grow as experience helps enhance efficiencies.  Web based EDC will help us significantly reduce our time to lock and allow us to get to market quicker than the 12 to 15 year average and allow us to squeeze additional sales out of the remaining patent life.  Web enabled EDC has the ability to minimize the ‘time to lock’ for each of the trial phases, potentially yielding an additional $360 in sales by getting us to market a full year earlier!  Web enabled EDC is the move to make and the time is now!

Regards,
Bobby Grau

No comments:

Post a Comment